28/11/24 -"The decline in the NAV valuation is largely attributable to the ongoing challenges within Eurofins' biopharma segment (29% of total revenue), as clients in the Clinical trials business in North ..."
Pages
59
Language
English
Published on
28/11/24
You may also be interested by these reports :
08/05/25
Organic sales growth and operating margin improvement were in line with expectations, with all divisions contributing to the overall performance. At ...
30/04/25
Rentokil’s (Buy; UK) share price has declined by 11% since we last teased about it in May 2024. Things started out well when the activist investor ...
25/04/25
BV’s Q1 sales figures were marginally ahead of the consensus in absolute terms, but exceeded expectations on organic growth. Sales growth was ...
24/04/25
SGS’s Q1 organic print was within the group’s guidance of 5-7%, with the organic growth 20bps below the company-compiled consensus, whereas absolute ...